John Simmons

John Simmons

Company: Natera

Job title: Global Vice President - Biopharma


The Use of ctDNA MRD in Clinical Development 9:30 am

Backed by >50 peer reviewed publications and >200 congress presentations, Signatera’s prognostic and predictive capabilities has been demonstrated across tumor histologies Signatera has been shown to identify high-risk patients who may benefit from investigational/novel therapies; more interventional trials are needed for these populations Rapid growth in Signatera utilization, especially in colorectal, breast, and bladder cancers,…Read more

day: Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.